Good day ladies and gentlemen, and welcome to the General Electric Third Quarter 2014 Earnings Conference Call. At this time, all participants are in a listen-only mode. My name is Vivian and I will be your conference coordinator today. (Operator instructions) As a reminder this conference is being recorded. I would now like to turn the program over to your host for today’s conference, Matt Cribbins, Vice President of Investor Communications. Please proceed.

Great, thank you. Good morning, and welcome, everyone. We are pleased to host today’s third quarter webcast. Regarding the materials for this webcast, we issued the press release presentation and GE Supplemental earlier this morning on our website at www.ge.com/investor. As always, elements of this presentation are forward-looking and are based on our best view of the world and our businesses as we see them today. Those elements can change as the world changes. Please interpret them in that light. For today’s webcast, we have our Chairman and CEO, Jeff Immelt; our Senior Vice President and CFO, Jeff Bornstein, and our Vice President, GE Healthcare Life Sciences, Kieran Murphy. We’ve asked Kieran to join to talk about our life sciences business. Now with that, I’d like to turn it over to our Chairman and CEO, Jeff Immelt.

Thanks, Matt. We continue to plan against the global macro backdrop to this volatile and one where some economic projections of recent been revised downwards. That said, we are seeing solid pockets of underlying growth in many of our markets. The good news for us is that we plan for volatile environment, our businesses are executing well, and we are tracking to our expectations for the year. As a result, we had a good quarter. EPS was $0.38, an increase of 6% versus last year. Our Industrial segment profits grew by 9%. Our relative position in key markets is improving. We’ve gained share in transportation, aviation, power and healthcare. We had great new products. Orders grew by 22%. For the first time in a while we are seeing volume improving for GE Capital in the US. GE grew margins by 90 basis points. We continue to generate benefits from our simplification efforts and are on track for more than $1 billion of costs out for the year. Margins improved in six or seven businesses and our costs out momentum are strong. We remain on track for CFOA for the year. So we are running the company well. And we are executing on our portfolio strategy. We launched the Synchrony IPO in July and as we move forward this will dramatically reduce the size of GE Capital and our presence in consumer finance and we’ve invested in platforms like Milestone Aviation, a helicopter leasing business linked to GE Aviation. So we are on track to create a smaller GE Capital focused on commercial finance. At the same time, we announced the sale of Appliances a legacy GE business. The Synchrony spend, Appliances sale and also some acquisition from the second quarter, are all a part of repositioning GE to be the…

Thanks, Jeff. Good morning and thanks for giving me the opportunity to tell you more about life sciences, a $3.7 billion business within GE Healthcare. The healthcare industry is moving towards a more precise diagnosis with more precise treatment to address an annual waste of $350 billion since most around 90% of currently marketed drugs, only work for about 40% of people. Precision medicine would improve patient outcomes and reduced healthcare costs and this is driving the demand for biologics as opposed to chemical medicines improving efficacy, and reducing side-effects. We are in a central component of drug manufacture for this industry. Our presence in life sciences extends from the research lab where we helped in the discovery of new medicines to the manufacturing plants where we deliver capacity and productivity. And then, all the way to supporting clinicians who use our diagnostic agents to make refined diagnosis for tens of millions of patients around the world every year. The expansion of biological medicines for the treatment of diabetes, cancer, rheumatoid arthritis and other diseases drives demand for GE products and services which are embedded in biopharmaceutical dugs. Today, these drugs make up six of the top ten revenue generating medicines. Also, in the emerging markets, particularly China, there is a growing market need for generic bio-drugs called bio-similars. This has the potential to be a significant growth opportunity over the next five to ten years. And the next evolution of medicines regenerative medicine, which is based on regenerating cells, tissues and organs in the body is an area where GE is investing for the future. All of this adds up to a market growing at around 8% per year. We have a broad portfolio of products which has driven into two main areas, bioprocessing and research serving academics and…

Thanks, Kieran. I’ll start with the third quarter summary. We had revenues of $36.2 billion, up 1% from the third quarter of 2013. Industrial sales of $26 billion were up 3% and GE Capital revenues of $10.5 billion were down 1%. Operating earnings of $3.8 billion were up 3% in the quarter. Operational earnings per share of $0.38 were up 6%, continuing EPS of $0.34 includes the impact of non-operating pension and net EPS includes the impact of discontinued operations. With a small benefit in discontinued operations this quarter associated with touring of taxes on the Grey Zone payment. As Jeff said, CFO year-to-date was $7.2 billion, with industrial CFOA of $5 billion and received $2.2 billion of dividends from GE capital. In the quarter , industrial generated $3 billion of CFOA, up $900 million versus the third quarter of 2013. For the year, we’re on track to deliver on the $14 billion to $17 billion framework we provided. The GE tax rate for the quarter was 18% and that brings the year-to-date rate for the industrial company to 20%. We expect the total year rate to be in the high teens. The GE Capital rate was 2% for the quarter and that was consistent with the low single-digit total year rate that we previously communicated. On the right side, you can see the segment results. Industrial segment revenues were up 3% reported and up 4% organically. Industrial segment operating profit was up 9% and GE Capital earnings were down 22% on lower assets, the Synchrony minority interest impact and lower tax benefits. I’ll cover the dynamics of each of the segments in the next couple of pages.. First I’ll start with other items for the quarter. We had $0.03 of restructuring other charges at corporate, $0.02 of that related…

Thanks, Jeff. We remain on track for a 2014 operating framework. Industrial segment earnings were driven by sustained organic growth and margin expansion and are expected to grow by at least 10% this year. GE Capital is on track with higher earnings in the fourth quarter, due to the timing of the Nordic consumer finance platform sale. Corporate is on track as expected and as expected, corporate has been a drag in 2014 because of restructuring investments exceed gains. However, this will be a real tailwind in 2015. Cash and revenues remain on track and we expect fourth quarter organic revenue to be robust. Despite a volatile global environment, GE expects to have a good fourth quarter and deliver on our 2014 framework. In addition, we are changing the portfolio to position GE for long-term growth. The GE team has done a good job of both strategic and operational execution. With a big backlog, high levels of recurring revenue and a restructuring program already in place,, we believe that GE will deliver for investors in times like these. Now, Matt let’s turn it back over to you and take some questions.

All right, thanks, Jeff, Why don’t we open up and take some questions now?

(Operator instructions) Our first question comes from Scott Davis. Please go ahead. Scott Davis – Barclays Capital: Hi. Good morning guys.

Hey Scott Scott Davis – Barclays Capital: Appreciate the detail on the presentation. It's really helpful. Guys, I wanted to get your sense, I mean, if you look at the markets, it’s kind of telling you that the world is falling apart, but then we see the numbers here and they look pretty – pretty darn good overall, and overall in the space haven't been that bad. I mean, \what are your customers telling you? I mean, is – are we at a risk of a real pullback in customer activity as we get into the fourth quarter just based on this new growth contagion that‘s out there – this growth fear?

You know, Scott, I just give you a view of the world and again, there is certainly lot going on but I would say, the US is probably the best we’ve seen it since the financial crisis, right, when you look at rail loadings and things like that, you’ve got a decent and healthy US market. Europe is slower for sure. But I think most companies, industrial companies haven’t counted on Europe and Japan for much incremental growth. And then if you go across the emerging markets and I was two weeks ago the Middle East and North Africa still pretty healthy robust. China, I think is more of a micro story then macro story now. Aviation, healthcare very strong, if you are in the right industries, very robust. Mexico better. So if you look at it geographically Scott, I think it’s kind of the slow growth pattern with volatility but a not a lot different than what we’ve seen in the past and then kind of industry-by-industry, Aviation remains strong, transportation remains strong, power, depends on what segments you are in. Or I guess, you definitely have more caution in oil and gas, but I’ve been with a bunch of the CEOs just in the last couple days and the long-term projects I think are still kind of underway. But there is certainly, I would say, there was already caution before the last, I would say, month or so around there. So, I think it fits a pattern that we’ve seen in the last couple of years and the underlying activity is still reasonably healthy but not universal. There are some parts that are clearly stronger than others. Scott Davis – Barclays Capital: Okay, fair enough. And just, healthcare, it's kind of unusual for you guys to make a big management change like that in the middle of a quarter or a middle of the year, I should say. The healthcare numbers were pretty good. I mean, what was it, Jeff, that you didn't like about the direction of what’s going on in healthcare that really catalyzed the change there?

You know, Scott, these things were always individual-by-individual. I think, John Dineen was a really good leader here; I think he has got good opportunities as you saw yesterday he has got a nice new assignment and sometimes I just think it works for the individual and for the company. So, again, I think the healthcare business is still a key business for us. But, yes, it gives us a new set of eyes and I think in John’s case, the future makes sense for him as well. Scott Davis – Barclays Capital: I normally don't ask three questions, but, what people are asking questions. Why put a non-healthcare, non-domain experienced guy into a business like this? I mean, Jeff, you’ve said in the past that, you really want more domain expertise within the businesses and John is – I think he is very good obviously, but it came it’s a little bit strange to put a non-healthcare guy in charge of the healthcare business. I mean, can you just explain that a little bit and then I’ll pass it on?

Yes, Scott, look, I love Flannery’s global experience. I thought that was outstanding. He has got a great strategic buying to put. He has more experience in healthcare than I had when I became of CEO of healthcare more than 10 years ago. So, I think he has got a nice – really a nice background and has real hands on experience with it outside the United States. Scott Davis – Barclays Capital: Okay. Fair enough. Thanks guys.

Yes, thanks, Scott.

The next question comes from Nigel Coe. Please go ahead. Nigel Coe – Morgan Stanley: Thanks, good morning.

Morning Nigel. Nigel Coe – Morgan Stanley: Yes, so I was quite obviously very pleased to get the detail on Life Sciences – a real gem of an asset. But relatively small in the theme of things, so I am wondering, Jeff, is this a business that you want to grow a bit more aggressively going forward from here?

Well, you know, there is still – maybe I’ll start and then Kieran turn it over to you. I think in the bioprocess manufacturing, we’ve been able to do bolt-on acquisitions behind organic growth and I think that’s been a great GE success factor over time. So, I think that’s falling of those one that we continue to make – get experience with. And then the other side on the diagnostic pharma side, Nigel, that’s more of a heavy R&D side. Right, so I would say, maybe bolt-on acquisitions on the bioprocess manufacturing, maybe some R&D collaborations, but I don’t see a big deal. And now Kieran why don’t I turn it to you?

Yes, I agree Jeff. Look, I think the prognosis for growth for this business is actually very strong. We have a great portfolio, especially in the bioprocessing space, we’ve done some nice deals here to give ourselves this stuff to finish to the receptor on the pitch and there is no question that with the innovation in medicine moving more towards biology and really strong continued growth in monoclonal antibodies, we are in a great position to serve that market. And of course, if you look at what’s happening in the emerging markets, especially in places like China, and the need for infrastructure, I think our solutions are ideally suited to that. So, I see a greater opportunity for growth. From our standpoint, the GE infrastructure globally gives us such a great reach into the markets, especially as with things like China, the Middle East and Latin America, that the infrastructure of GE gives us a great backbone to actually reach into these markets and do projects in difficult situations. Nigel Coe – Morgan Stanley: Okay, thanks. And then, Jeff, as a follow-on expressing confidence in the 7% organic for the year is obviously encouraging given the headlines, but you clearly have the backlog in place, but you talked about some deferrals into 4Q, maybe 2015, in oil and gas and perhaps power. So I am wondering to what extent that you are concerned that perhaps these delays might push into 2015 and therefore maybe 4Q comes in a bit weaker? So what gives you confidence that GE can get the 7% for the year?

I would talk about – I wanted to – the power stuff is really the hub of – kind of- I guess our confidence and I don’t know, Jeff do you want to?

Yes, I mean, we have fourth quarter in front of us that we think is kind of be very strong. Just for instance, year-over-year in the fourth quarter, our gas serving shipment is going to be up more than 40% year-over-year. Our wind shipments will be up more than 30% year-over-year. Aero shipments 16%, even commercial and military engines are going to be up mid double-digits and we are looking for a 30% increase in locos year-over-year. So we are looking at a fourth quarter that we think is going to be very strong and we expect the power business to be up substantially in the fourth quarter.

And this stuff – that’s already cited and financed and then backlog and stuff like that.

Yes, for the most part, most of the gas turbines or 100% of the gas turbines are in backlog, we are in good shape on wind. So a good part of the volume that drives the fourth quarter. We stand pretty firmly on – I would say, as I’ve said before, distributed power is the place where we have seen the most volatility and based on the places we are selling, I think, that’s going to continue to play out that way. But, I think, we feel good about a strong revenue quarter in the fourth quarter. Nigel Coe – Morgan Stanley: That's very helpful and just a quick follow-on to that. So, obviously based on equipment orders, shipments in place for 4Q, normally that would dent margins, but you had service margins up so strong in this quarter. So, I am wondering, can you maybe add some color on where you look for margin in 4Q as well?

No, we continue to progress on where we expect to continue to progress on margins. We are on this journey to 17 plus percent 2016, we got, we’re 50 basis points up third quarter year-to-date. And we expect to be on that trajectory to get to 17% in 2016. So, we would expect to continue to progress.

I just think tailwinds, the micro stuff, SG&A is good, value gap is good and I think the service productivity actually has good momentum as well. Nigel Coe – Morgan Stanley: Okay. Thanks, Jeff.

The next question comes from Steven Winoker. Please go ahead. Steven Winoker – Sanford Bernstein: Thanks and good morning.

Hey, Steve. Steven Winoker – Sanford Bernstein: Hey, so, maybe just it's been a little while now that you’ve been moving forward with Alstom. How has your thinking continued to progress as the time has passed? We got another quarter of information behind us from Alstom and within your business. Where are you in the process and how are you thinking about the opportunity now versus a few months ago?

You know, Steve, here is what, again, we’re just in the process itself. I think the regulatory stuff is all going per schedule. We haven’t seen anything that is a surprise. They are in the same markets out that you guys see every day. So, some good some bad on that, but, not a big surprise there and I would say synergies, the opportunities for synergies are probably greater than what we would have expected and so we continue to work on that. So, I think, other than that, I don’t really – there is not a lot more color I can add – I’ll do more at the outlook meeting on Alstom. But, I’d say, we still like what we see. We still think there is good potential to run it as a combined entity better. Steven Winoker – Sanford Bernstein: Okay and then, maybe just going – diving a little bit into the order price profile on, Slide 3 obviously it’s pretty positive across most of those segments and then we saw yet another quarter where healthcare was negative and kind of used to that at this point. And obviously, you called out the positives going on in life science. So maybe just continue to give us a little understanding, obviously this must be within systems. And kind of what’s happening? Is there any change here? How the Affordable Care Act you are seeing sort of play out so far? And maybe, are you looking at this thing with a little more of a fresh eye these days, just some thoughts on that front?

You know, I think healthcare has been, everything else being equal reasonably consistent for quite a long period of time. I mean, we have seen quarter-over-quarter, year-over-year equipment pricing in the down 140 basis points, roughly 150 basis points at a point in time. A little bit better on service. But I don’t think we see anything that would suggest that the dynamics around those product cycles, the market behavior, around price is changing. So, we are very focused on winning with technology and gaining share that way and as I said, we had a reasonably for the first time – reasonably strong equipment market here in the US for us up 10%. We don’t think the market was up that. So, we need to win on technology and execution and I think the price dynamics on equipment and imaging are what they are and I don’t see anything changing there.

Steve, there is a little bit that’s of healthcare on the high tech learning curve. So, you get RCM rates are equal to or greater even sometimes when the price is down because we are getting the cost down and the product as well. So, it has the unique – I would say visibility or and compared to some of other products and technologies.

And our next question comes from Steve Tusa. Please go ahead. Steve Tusa – JPMorgan: Hey, guys. Good morning.

Hey, Steve. Steve Tusa – JPMorgan: So, you got a big – obviously a big equipment number coming through in the fourth quarter. There will be a bit of a mix impact. I think you gave some color on the margin; it seems like it’s going to be up. Maybe if I just look at normal seasonality, which has been pretty consistent in the last few years and profits, 3Q to 4Q you guys have been up about 37%, 38%. Will you be up similarly in the fourth quarter from an operating profit, industrial profit perspective, so somewhere around low 6 to 6.1 type of number for the fourth quarter or it will be better than normal seasonality?

No, we expect to be up obviously with the higher volume in the fourth quarter and we expect to continue to build on the cost gains that we’ve had throughout the year both in terms of SG&A and corporate cost. So, we are expecting an increase in profit. We expect to earn more in the fourth quarter for sure and we are expecting strong double-digit revenue growth and we expect to continue to make progress on margins. Steve Tusa – JPMorgan: Right. So I guess from a – will it be less than the 50 BPS in the fourth quarter year-over-year? I mean it sounds well like the mix is going to be tough.

We have a very heavy equipment quarter in the fourth quarter for sure. But as I said, we expect to make progress on margins for the year. We expect to stay on that trajectory to get the 17 plus percent in 2016. So, the 15 basis points in the third quarter, I would expect those to have a decent year. Steve Tusa – JPMorgan: Okay and then one last question just on the turbine forecast for next year. You guys have the orders are – sales are a little bit higher; orders are a little bit lower, can you still grow your turbine shipments next year at this stage of the game?

Steve, we’ll give you – when we do the outlook meeting in December, we’ll give you a little bit more color on kind of what we are thinking about 2015. There is also going to be there is starting to be, Steve, a higher mix on big units as well. So, you just will try to spell that all, but you definitely see the market mixing towards the bigger units.

And our next question comes from Deane Dray, please go ahead. Deane Dray – Citigroup: Thank you. Good morning, everyone.

Hey Deane. Deane Dray – Citigroup: Hey, on Synchrony, the timing of the split-up transaction, I know you are saying late 2015 it depends on regulatory approvals. But, for modeling purposes, what do you suggest that we’d be using?

Yes, you are right. We’re hopeful that we can get the exchange executed in late 2015. If I were modeling actually, I think I would just model Synchrony in the year and the exchange happening on 1-1 of 2016. We can’t tell you today exactly when in late 2015, I think for modeling purposes, I would have it in for the year. Deane Dray – Citigroup: Great, that's helpful. And then showcasing Life Sciences today, we talked a lot about growth. Maybe you can share with us what the returns have been on these investments and I don't know if you can still trace back to the returns on Amersham, but maybe start there?

Yes, we’ve looked at that. If you go back I believe Amersham was done in 2004, when we go back and look at it, over the last roughly ten years, in this business we’ve collected about $10 billion of cash. Obviously, we had the Amersham investment, we have several other investments along the way. We’ve got order of magnitude $13 billion invested. If you look at business today at a $1.1 billion to $1.2 billion of EBITDA, we think the multiple, if you split it the way Kieran described it, if you think about biopharma and research there is a very multiple of EBITDA based on transactions Merck and others have done. And the Diagnostics business being a lower multiple business, lower growth, lower margin, at 15.5 times those EBITDA numbers you get a total value of – call it 20 – I am sorry, $27 billion, $17 billion is what we got today roughly, $10 billion of cash collected versus the $13 billion we got into it. You get a kind of something like a low teens IRR if you will like today. Now, having said that, we think Kieran has got his business accelerating from here and we are very bullish on the biopharma space and so we think the returns from here forward are going to be more attractive than that. I don’t know if I answered your question.

And our next question comes from Jeff Sprague. Please go ahead. Jeff Sprague – Vertical Research Partners: Thank you. Good morning, everyone.

Hey, Jeff. Jeff Sprague – Vertical Research Partners: Good morning. Just a couple quick ones. Jeff, you noted the unit outlook is a little cloudier on energy now taken the size of units that are moving up. But, I think the color in the quarter was thermal order dollars were down, but you had higher gigawatts in orders. Can you give us a little bit of color then what is really going on, on new unit pricing and does that imply that these first H units really go out at very, very tough pricing?

Sure, so, it’s heavily dynamic with the H. As we talked about, we’ve got 13 in backlog and we have customers – some customers that are rethinking what otherwise might have been F powered capacity with H cop powered capacity. It is generally speaking it’s one H unit will replace two F units. So, on the pricing front, the initial, these are launch orders, so the initial H orders are going to be tougher, no question about that and we’ll get down the cost curve as quickly as possible. But I think generally speaking, we think the technology has been incredibly well received and where we thought we would be if not better given the early 2014 launch of the technology. So, we feel like we are more competitive. We had a great quarter in the US, it took 11 units.

I think the other dynamic, Jeff, that I would talk about Jeff is, the mix of regions is probably better. So the US is probably the place where there is the most interest right now. And that has tended to be a slightly better margin type region for us. So, that’s a positive. Jeff Sprague – Vertical Research Partners: All right and I am just trying to understand kind of the disconnect between power and water order price up 1.3%.

I got you, I am sorry, Jeff. Yes, I got it, I am sorry. The H turbines, because they are new, they are not in the OPI number. There is no price to compare to last year. Jeff Sprague – Vertical Research Partners: Okay.

I am sorry. I misunderstood the question. Jeff Sprague – Vertical Research Partners: Well, you partially got what I wanted to know too; but, there was a second element implied, so I appreciate that. And then, just on, maybe stepping back to the Milestone deal, maybe I wasn't thinking about at this way, but kind of focusing on the core in GE Capital, I didn't really think that meant M&A was on the table. I thought that was probably more an organic idea. What is your appetite for M&A in Capital moving forward?

So, Jeff, here is what I’d say, this is a strike zone deal for what we do in GCAS. We know how to do this. It’s an operating lease business. It matches very well with our footprint geographically on where we have resources and operating capabilities deployed. We know how to manage businesses like this that are very asset-intensive and we really like what the returns look like over time. It also lines up like GCAS does with our aviation business. So a very high percentage of this portfolio, our GE powered helicopters and we think that provides a lot of synergy. So, we’ve been – I think reasonably consistent saying that we were going to continue to grow our core mid-market and industrially aligned verticals as we move forward and at the same time, we are very aggressively working the $135 billion of non-strategic parts of the portfolio and we’ve got a lot of things in motion there. So, I think, the other way you need to think about it a bit is, we’ve got capital available and we’d rather deploy the capital at very attractive returns than to put the capital to work in a bank at a negative carry. So, I think this makes all the sense in the world and I don’t think in anyway is that inconsistent with anything we or Keith have communicated.

Thank you and our next question comes from John Inch, please go ahead. John Inch – Deutsche Bank: Thanks. Good morning, everyone. Just given these puts and takes in Power & Water between orders and heavy shipments and I know there is a – it’s got such a big influence on cash flow, Jeff Bornstein, are we thinking that operating cash for the year is going to be kind of towards the lower end of the $17 billion or is it close to call?

Today, – as we sit here today, I would say we expect to be about the midpoint of the range. So we’ve got a big fourth quarter in front of us, no question about it. If you think about last year we did $5.5 billion of CFOA industrial in the fourth quarter based on the earnings improvement what we expect to get from a working capital improvement by liquidating all that inventory. In the fourth quarter, we think we’ve got to pass to be about mid-point of the range between $14 billion and $17 billion.

We would have much higher industrial earnings, John, and much higher shipments. So we ought to have a good fourth quarter, I’d say on cash. John Inch – Deutsche Bank: Okay and then FX, one of the dynamics at GE that makes you different is just you carry high value of your equipment versus other industrial companies. So, it could be for either of you, I mean, does FX and the decline of the euro and the yen, does that open a door to Mitsubishi and Siemens really to become much more aggressive on the OE pricing that could influence sort of the dynamic going forward? How are you thinking about it based on if anything known so far?

I’d say, listen, a great part of our industrial footprint here is that we make protocol over the world. So, we can be flexible, but where we make product, if FX becomes that big an issue, we can be flexible about where we make products. So I don’t think we are anticipating FX being a competitive issue for us.

I would echo that, John, I think the dynamic is really one where we’ve got the right global footprint to do whatever ultimately we need to do.

And our last question comes from Andrew Obin. Please go ahead. Andrew Obin – Bank of America Merrill Lynch: Yes, good morning.

Hi, Andrew. Andrew Obin – Bank of America Merrill Lynch: Hi, just a question. You sort of highlighted H turbines being successful and some of your customers really looking into them, but you also said that it requires some re-permitting. How disruptive could it be and could we see a pause in North American cycle because of that?

No, as you know, I think, in North America, I think a lot of that planning is already underway. So I would say Andrew not much. I think the whole product line is well positioned and it’s great to have a large block of turbines. But we also are still seeing activity on the other turbines as well. So, I think, other than the 13, we’ve got another 15 Hs that are out there kind of being globally which should enter the backlog sometime eminently and so, we are just seeing pretty good momentum there and I don’t see it disrupting the – let’s say the flow from commitment to order to revenue. Andrew Obin – Bank of America Merrill Lynch: Sure, now quickly if I could just squeeze one more in. Measurement and Control, could you just give us a little bit more color? How it’s improving and where we are on the call within that division?

So the organic, we’ve done some dispositions there, Andrew. So, I think the organic is up mid-single-digits kind of range 7% something like that.

Yes.

And so, we’ve seen that be pretty decent in the last quarter.

So, I would say, excluding the disposition impacts, the M&C businesses has start to turn a little bit organically. Orders in the third quarter were up 7%, revenue was – I said in the script were up 8% and they are getting some operating leverage. And so, we’ve seen a little bit of more strength in oil and gas applications and industrial applications around controls. And so we are hopeful that we are trending more positively here in the M&C business as you know that’s important, it’s a very profitable business for oil and gas.

Matt, I want to just

Sure.

Before we cut off today, I think we talked a lot about execution in the quarter, but I wanted to elevate just a bit. We really remain on track to get the company at 75% industrial, 25% GE Capital, while growing EPS every year, this year next year and into the future. And I think in addition to the good execution in the quarter, the strategic moves the company continues to make to – with Alstom, Appliances, remixing GE Capital continues to make this a more valuable company. So I think that’s an addition to the current quarter operations. I think we are executing on the portfolio to create a much more valuable company.

Great, thank you, Jeff. Couple of quick announcements. The replay of today’s webcast will be available this afternoon on our website. We will be distributing our quarterly supplemental data for GE Capital later today. We have two upcoming investor events. The first on Tuesday December 16 we will hold our Annual Outlook Meeting in New York City and on Friday, January 23, we’ll hold our fourth quarter 2014 earnings webcast. As always we will be available today to take your questions. Thank you